SODIUM NITROPRUSSIDE FOR INJECTION DIN 02542129
Status: Marketed
Holder: JAMP PHARMA CORPORATION
Health Canada record
| Active ingredient(s) | SODIUM NITROPRUSSIDE (SODIUM NITROPRUSSIDE) 25 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C02DD01 NITROPRUSSIDE |
| Original market date | 13-Feb-2025 |
| Current status date | 13-Feb-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 31952 | 2023-10-27 | Abbreviated New Drug Submission (ANDS) |